KGMU study offers new relief options for chronic heel pain
The study, 'Ultrasonography-guided dextrose prolotherapy versus platelet-rich plasma injections for the treatment of Plantar Fasciitis', was published in the journal Cureus in Feb. Researchers from KGMU's physical medicine and rehabilitation (PMR) department found two regenerative methods — dextrose prolotherapy and platelet-rich plasma (PRP) injections.
Lead researcher Prof Sudhir Mishra said that chronic heel pain is due to damage to the thick tissue under the foot and often difficult to treat with conventional methods.
This affects about 10% of people, especially women in 40-60 age group and athletes. Traditional treatments like rest, stretching, orthotics, corticosteroids and physical therapy often help, but many patients still experience pain.
The study involved 44 patients unresponsive to standard treatments. They were split into two groups — one received ultrasound-guided 25% dextrose injections, the other PRP from their own blood.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Cat Keeps Hugging Friend Before Going To The Vet – The Vet Paled When He Saw Them
Tips and Tricks
Undo
After six weeks, both groups reported less pain and improved foot and ankle function. PRP showed slightly better results, but differences were not always significant.
Prof Mishra said these minimally invasive injections are well tolerated and can greatly improve the quality of life for patients who do not respond to conventional treatments. Although PRP is more costly and complex to prepare, both treatments are safe, effective and can be chosen based on patient needs.
The study supports growing evidence for regenerative medicine in chronic musculoskeletal pain.
Physical medicine and rehabilitation department head, Prof Anil Kumar Gupta, said treatment usually starts with rest, special insoles and sometimes steroid injections, which work well in early or mild cases. When traditional methods fail, regenerative therapies like dextrose prolotherapy and PRP are considered.
Both stimulate tissue repair — dextrose needs multiple injections and lasts shorter, while PRP often requires a single injection and lasts longer.
Prof Mishra said dextrose costs about Rs 500-700 per session, including ultrasound guidance, making it more affordable. PRP costs Rs 3,000-3,500 due to specialised processing but requires fewer sessions. PRP is especially effective for long-term pain lasting months or more.
Using the patient's own blood lowers allergy risks and can work when other treatments fail.
Choice depends on pain duration and severity. For pain lasting a week or two, traditional methods suffice. For pain over a month, dextrose prolotherapy may be advised. For pain lasting three months or more, especially if other treatments fail, PRP is preferred. Dextrose typically requires 2-3 injections spaced 15 days apart, while PRP usually needs one injection, with a second dose for severe cases. Both are effective, but PRP tends to offer better pain relief and longer recovery.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Probe panel set up as man claims drug sale at Ropar rehab centre
1 2 Patiala: A viral video, in which a patient alleged that drugs were being sold inside a govt-run de-addiction centre at the civil hospital in Ropar, has led to the formation of a three-member probe panel. In the video, the man also shows alleged drug-related items and accuses staff of facilitating the distribution of narcotics. Former Punjab chief minister and serving Congress MP Charanjit Singh Channi shared the video on social media on Saturday, calling it the "real face" of the Aam Aadmi Party govt's anti-drug campaign, 'Yudh Nashian Virudh'. "This is the ground reality of the so-called war on drugs. The govt must be held accountable," he wrote. Ropar deputy commissioner Varjeet Walia has since ordered an investigation by a three-member committee comprising the local SDM, Ropar civil surgeon, and a DSP. The panel has been directed to submit its report within a week. Ropar civil surgeon Dr Balwinder Kaur said a preliminary inquiry had found the claims to be "factually incorrect" and orchestrated by "anti-social elements". She claimed that the de-addiction centre had 36 patients, all receiving free treatment, with 28 of them undergoing care under Order 64-A of the NDPS Act. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like You Won't Believe the Price of These Dubai Apartments Binghatti Developers FZE Get Offer Undo The probe found no illegal substances on the premises, she said. "The video content is misleading and does not reflect the actual situation at the centre," Dr Balwinder Kaur said. She added that during the preliminary inspection, all staff, security personnel, and police were found on duty, maintaining hygiene and patient care standards. Patients interviewed during the inquiry expressed satisfaction with the treatment being provided, she said. Dr Balwinder added additional measures had also been implemented. "The centre is staffed with seven security guards and eight ward attendants, with 24/7 surveillance by Ropar police. A woman security guard will also be deployed to enhance oversight, and thorough checks of patients and their visitors have been made mandatory," she said.
Time of India
an hour ago
- Time of India
Kidney ailments top list of treatments under Aarogyasri
Status: Done Hyderabad: Majority of the treatments provided under the Telangana govt's flagship Rajiv Aarogyasri healthcare scheme over the past two years have been for kidney-related issues, with over 2.1 lakh such cases recorded, officials revealed on Saturday. Tired of too many ads? go ad free now During the same period, free medical care was extended to over 10.7 lakh people under the scheme. The scheme aims to provide accessible healthcare to families living below the poverty line (BPL). Following kidney treatments, the highest number of cases were for cancer (1,90,447), polytrauma (88,117), urinary surgeries (81,982) and general medicine (81,611). Hyderabad topped the list with over 1.25 lakh patient cases, followed by Rangareddy (68,343 cases), Nalgonda (59,071) and Medchal-Malkajgiri (52,359 cases). With the annual treatment cap doubled from Rs 5 lakh to Rs 10 lakh per family, officials said the enhancement enabled access to high-cost secondary and tertiary interventions, reducing out-of-pocket expenses and allowing procedures that were previously financially out of reach. This, the officials say, brought the number of procedures covered under the scheme to 1,835, including 163 advanced treatments, and also led to an increase in package rates for 1,375 such procedures by 25%. These rates were last fixed in 2012 and have not been revised since then. "The enhancement of financial cap empowered families to seek timely and quality treatment without the burden of financial stress. It has significantly increased the scheme's reach and utilisation, encouraging more hospitals to join the network, and brought advanced healthcare services closer to people, particularly in rural and remote areas. Tired of too many ads? go ad free now Above all, it has instilled a renewed sense of confidence and security among citizens, ensuring that health is no longer a privilege, but a right for every family," P Uday Kumar, CEO, Rajiv Aarogyasri Health Care Trust (RAHCT), told TOI. With a total of 108 private hospitals also empanelled under the Aarogyasri network over the past year, as many as 461 private and corporate hospitals now offer healthcare services under the scheme across the state. "The majority of these 108 hospitals in the network are located outside Hyderabad. This has increased access to specialised care closer to patients' homes, particularly in backward areas, and reduced travel time and delays in treatment. Moreover, the number of BPL families under the scheme also significantly increased in this time period," said another official of the RAHCT. Meanwhile, a total of ₹1,590 to the network of hospitals over the last 20 months was also cleared.
Time of India
an hour ago
- Time of India
Carcinogens: ICMR to study samples
New Delhi: The Indian Council of Medical Research (ICMR) submitted a reply to the National Green Tribunal stating that it will soon initiate a study by collecting blood and urine samples of drivers to evaluate whether chemical compounds called TCEP, TCIPP and TDCIPP found in flame retardants materials used in the cars are potentially carcinogenic. The response comes in the wake of a study published in journal Environmental Science and Technology saying that cars have flame retardant chemicals considered potentially carcinogenic. The study was concerned about Tris (1-chloro-isopropyl) phosphate (TCIPP), Tris (1,3-dichloro-2-propyl) phosphate (TDCIPP) and Tris (2-chloroethyl) phosphate (TCEP). Of these, ICMR has already recognised TCEP as a carcinogen. A bench headed by NGT chairman, justice Prakash Shrivastava, had sought details about the matter. Responding on July 22, ICMR said it intends to test 360 professional drivers by collecting their urine and blood sample to test for presence of the chemical compounds. The study could take at least 18 months. The proposal of ICMR-NIOH, Ahmedabad, would detail the study objectives, methodology, budget requirements, as well as timelines for conducting the research, ICMR told NGT. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Seniors Say This Drugstore Wrinkle Cream Is Actually Worth It Best Of Beauty Learn More Undo Some of the objectives would be to assess exposure of flame retardants and their metabolites among professional drivers and to compare biological levels of flame-retardants/their metabolites in "variable climatic conditions and vehicular stratification". You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi "As per the proposal, the above mentioned research study would involve a zone-stratified bio-monitoring. In terms of the proposal, completing laboratory analysis of biological samples, data processing, statistical valuation, exposure modelling, and reporting would require approximately 18 months," ICMR said. "Apart from the time period mentioned above, since a budgetary requirement of approximately Rs 85,32,800 is involved to conduct the proposed research study, due sanction and approval have to be obtained from the authorities concerned. Therefore, additionally, a period of nine months approximately would be required in obtaining the said requisite approvals/sanctions." Earlier in May, an ICMR report referred to several leading international agencies, including the International Agency for Research on Cancer under the World Health Organization and environment and toxicology institutes in the US and Europe having published systematic reviews identifying carcinogenic chemicals in flame retardants used in motor cars to which humans may be exposed through ingestion, inhalation or skin contact. The report said that only one of the compounds, namely TCEP, appeared on the list of potential carcinogens, while others did not. In response, NGT had requested a more detailed analysis of the compounds.
